SYNEXPRESS
LIVE

Serial Number

98634122

Owner

SYNGENE INTERNATIONAL LIMITED

Attorney

Lauren K. Tagarao

First Use Date

Feb 12, 2025

Filing Date

Jul 5, 2024

Add to watchlist:

No watchlists yet
View on USPTO

SYNEXPRESS Trademark

Serial Number: 98634122

SYNEXPRESS is a trademark filed by SYNGENE INTERNATIONAL LIMITED on July 5, 2024. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

SYNGENE INTERNATIONAL LIMITED (13 trademarks)

Biocon Special Economic Zone,Biocon Park
Link Rd, Bangalore Karnataka , IN

Entity Type: 03

Trademark Details

Filing Date

July 5, 2024

Registration Date

Not Registered

First Use Anywhere

February 12, 2025

First Use in Commerce

March 18, 2025

Published for Opposition

October 28, 2025

Goods & Services

Contract manufacturing and custom manufacture for biopharmaceutical companies for process development of manufacturing process of biologics being industrial chemicals in the fields of cell line development, clone selection, analytical methods, formulation, scale-up of the manufacturing process, manufacture of drug substance and drug product, viral testing, and viral clearance studies

Scientific research and development for biopharmaceutical companies in the field of biologics being antibodies, proteins, cells, and nucleic acids; custom design and development of chemical regents and biochemical assays being biochemicals and biopharmaceuticals; laboratory testing of materials; laboratory testing of materials services; testing of pharmaceuticals; biochemical engineering; biopharmaceutical drug development services being pharmaceutical drug development services; biopharmaceutical products development being research and development of new products; biopharmaceutical substance and products manufacturing being research and development of new products; development of pharmaceutical preparations and medicines; scientific study and research in the fields of reproduction, husbandry, and general health of animal; biotechnology research being scientific research for determining the neuronal survival of molecules in animal models; scientific research and development services in the fields of proteins, antibodies, antibody technology; custom design and development of biochemical reagents being chemical reagents and biochemical assays; design, engineering, research, development and testing services of new products for others in the fields of biochemicals, materials customization for medical, scientific, and technological applications; viral testing services being product quality testing services; viral testing analysis being chemical analysis; toxicity testing for research purposes being chemical analysis; conducting and providing tests being chemical analysis and supporting analysis for clinical trials being chemical analysis; providing medical and scientific research information in the field of clinical trials; conducting early evaluations in the field of new pharmaceuticals; scientific research being analytical services for scientific research purposes; laboratory research in the field of chemistry being protein expression; scientific research services relating to the isolation and cultivation of human tissues and cells; scientific research being preparation of reports relating to scientific and technical research; scientific research being analysis in the field of molecular biology; scientific research being contract research services relating to molecular sciences; biological cloning services; structural and functional analysis of genomes; scientific laboratory services; services of a chemical and biological laboratory being scientific laboratory services; laboratory research services relating to pharmaceuticals; scientific research and development and scientific research consultation in the fields of antibodies, antibody technology, chemistry, bioinformatics, biomedical, biologics, biotechnology, biotherapeutics, biology, biochemical, cell line, chemoinformatic, genetics and genetic engineering, gene expression systems, in vitro, inhalation pharmaceuticals, molecular sciences, micro-organisms, nutrition, and ophthalmic; scientific and technological services, namely, scientific research, scientific development, analysis, testing, engineering, extraction being scientific development, synthesis being scientific development, purification being scientific development, and production being scientific development in the fields of antibody, application programming interfaces, biomolecules, cell bank characterization, chiral, chromosome aberration, clinical chemistry, cloning vector, DNA, flow cytometry, mass spectrometry, gene, immuno-pharmaceuticals, in vitro assays, large molecule, liquid chromatography mass spectrometry, microbial, monomer, nanoparticle, natural products, peptides, proteins, RNA, supercritical fluid chromatography, and vaccines

Filing History

STATEMENT OF USE PROCESSING COMPLETE
Aug 11, 2026 SUPC
USE AMENDMENT FILED
Jun 18, 2026 IUAF
TEAS STATEMENT OF USE RECEIVED
Jun 18, 2026 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Dec 23, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Oct 28, 2025 NPUB
PUBLISHED FOR OPPOSITION
Oct 28, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Oct 22, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 30, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Sep 24, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Sep 24, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Sep 24, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Sep 24, 2025 CNEA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 14, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 14, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 14, 2025 REAP
TEAS/EMAIL CORRESPONDENCE ENTERED
May 8, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 8, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 8, 2025 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
May 1, 2025 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
May 1, 2025 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 1, 2025 GNRN
NON-FINAL ACTION E-MAILED
Feb 1, 2025 GNRT
NON-FINAL ACTION WRITTEN
Feb 1, 2025 CNRT
ASSIGNED TO EXAMINER
Jan 22, 2025 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 14, 2025 NWOS
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 4, 2024 CHAN
ASSIGNED TO LIE
Dec 4, 2024 ALIE
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Oct 18, 2024 EWAF
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Oct 18, 2024 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 18, 2024 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 18, 2024 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 18, 2024 REAP
NEW APPLICATION ENTERED
Jul 5, 2024 NWAP